FR10C0016I2 - METHODS AND COMPOSITIONS FOR THE TREATMENT OF GLOMERULONEPHRITIS - Google Patents

METHODS AND COMPOSITIONS FOR THE TREATMENT OF GLOMERULONEPHRITIS

Info

Publication number
FR10C0016I2
FR10C0016I2 FR10C0016C FR10C0016C FR10C0016I2 FR 10C0016 I2 FR10C0016 I2 FR 10C0016I2 FR 10C0016 C FR10C0016 C FR 10C0016C FR 10C0016 C FR10C0016 C FR 10C0016C FR 10C0016 I2 FR10C0016 I2 FR 10C0016I2
Authority
FR
France
Prior art keywords
glomerulonephritis
compositions
treatment
methods
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR10C0016C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22888581&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR10C0016(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Publication of FR10C0016I1 publication Critical patent/FR10C0016I1/fr
Application granted granted Critical
Publication of FR10C0016I2 publication Critical patent/FR10C0016I2/en
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

Anti-C5 antibodies and their therapeutic uses.
FR10C0016C 1994-05-02 2010-03-19 METHODS AND COMPOSITIONS FOR THE TREATMENT OF GLOMERULONEPHRITIS Active FR10C0016I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/236,208 US6074642A (en) 1994-05-02 1994-05-02 Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
PCT/US1995/005688 WO1995029697A1 (en) 1994-05-02 1995-05-01 Methods and compositions for the treatment of glomerulonephritis and other inflammatory diseases

Publications (2)

Publication Number Publication Date
FR10C0016I1 FR10C0016I1 (en) 2010-04-30
FR10C0016I2 true FR10C0016I2 (en) 2011-04-01

Family

ID=22888581

Family Applications (1)

Application Number Title Priority Date Filing Date
FR10C0016C Active FR10C0016I2 (en) 1994-05-02 2010-03-19 METHODS AND COMPOSITIONS FOR THE TREATMENT OF GLOMERULONEPHRITIS

Country Status (15)

Country Link
US (2) US6074642A (en)
EP (5) EP2298808A1 (en)
JP (5) JP3734266B2 (en)
KR (2) KR100442019B1 (en)
AT (1) ATE448791T1 (en)
AU (1) AU2474795A (en)
BR (1) BR9507594B8 (en)
CA (2) CA2189015C (en)
DE (2) DE69536017D1 (en)
DK (1) DK0758904T3 (en)
ES (1) ES2336051T3 (en)
FR (1) FR10C0016I2 (en)
NL (1) NL300433I2 (en)
PT (1) PT758904E (en)
WO (1) WO1995029697A1 (en)

Families Citing this family (266)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395888B1 (en) * 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
JP3971797B2 (en) * 1994-09-23 2007-09-05 アレクション・ファーマシューティカルズ・インク Method for treating inflammatory joint diseases
US7112327B2 (en) 1998-02-20 2006-09-26 Tanox, Inc. Inhibition of complement activation
EP2848634A1 (en) 1998-02-20 2015-03-18 Genentech, Inc. Inhibitors of complement activation
US6956107B2 (en) 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
DE19913707A1 (en) * 1999-03-26 2000-10-05 Privates Inst Bioserv Gmbh Immunosorbent for sepsis therapy
EP1196562A4 (en) * 1999-06-29 2007-01-10 Autogen Res Pty Ltd Novel genes and their use in the modulation of obesity, diabetes and energy imbalance
WO2001084149A2 (en) 2000-04-29 2001-11-08 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
EP1325033B1 (en) * 2000-10-10 2009-11-25 Genentech, Inc. Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
US20020094332A1 (en) * 2001-01-18 2002-07-18 Alexion Pharmaceuticals Method of prophylaxis against large myocardial infractions
CA2438652A1 (en) 2001-02-19 2002-09-06 Merck Patent Gesellschaft Mit Beschraenkter Haftung Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
US20030109714A1 (en) * 2001-03-22 2003-06-12 Neil Wishart Transition metal mediated process
WO2003009803A2 (en) * 2001-07-26 2003-02-06 Alexion Pharmaceuticals Inc. Method of improving cognitive function
EP3372243A1 (en) 2001-08-17 2018-09-12 Genentech, Inc. Complement pathway inhibitors binding to c5 and c5a without preventing formation of c5b
WO2003015819A1 (en) * 2001-08-17 2003-02-27 Tanox, Inc. Complement pathway inhibitors binding to c5 and c5a without preventing formation of c5b
WO2003048321A2 (en) 2001-12-03 2003-06-12 Alexion Pharmaceuticals, Inc. Hybrid antibodies
US20050221382A1 (en) * 2002-03-18 2005-10-06 Rother Russell P Stratification of patient populations having or suspected of having rheumatoid arthritis
ITMI20021527A1 (en) * 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche C5 COMPONENT ANTIBODIES OF COMPLEMENT AND THEIR USE
AU2003270330B2 (en) * 2002-09-06 2009-07-30 Alexion Pharmaceuticals, Inc. Method of treatment of asthma using antibodies to complement component C5
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
US7361339B2 (en) * 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
WO2005072380A2 (en) * 2004-01-28 2005-08-11 Chauhan Anil K Membrane attack complexes associated with circulating immune complexes
US20050169921A1 (en) 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US20070116710A1 (en) * 2004-02-03 2007-05-24 Leonard Bell Methods of treating hemolytic anemia
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
CA2566716C (en) * 2004-05-14 2014-12-23 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
US7973134B2 (en) * 2004-07-07 2011-07-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
US7935790B2 (en) * 2004-10-04 2011-05-03 Cell Singaling Technology, Inc. Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
US7807789B2 (en) * 2004-12-21 2010-10-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
US20090099340A1 (en) * 2007-10-12 2009-04-16 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
US20070292421A1 (en) * 2005-07-28 2007-12-20 Feinberg Bruce B Method for treating preeclampsia
EP1934867A2 (en) 2005-08-31 2008-06-25 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
US20100151495A9 (en) * 2005-08-31 2010-06-17 Cell Signaling Technolgy, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
KR20170002684A (en) 2005-11-04 2017-01-06 제넨테크, 인크. Use of complement pathway inhibitors to treat ocular diseases
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
US20070196367A1 (en) * 2006-02-22 2007-08-23 Valentin Dinu Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system
SG171578A1 (en) 2006-03-02 2011-06-29 Alexion Pharma Inc Prolongation of survival of an allograft by inhibiting complement activity
KR101513308B1 (en) 2006-03-08 2015-04-28 아케믹스 엘엘씨 -5 complement binding aptamers and anti-c5 agents useful in the treatment of ocular disorders
EP4316465A3 (en) * 2006-03-15 2024-04-24 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
CN104761637B (en) 2006-03-31 2021-10-15 中外制药株式会社 Method for regulating antibody hemodynamics
WO2007127335A2 (en) * 2006-04-27 2007-11-08 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in atm and atr kinase signaling pathways
AU2006343402A1 (en) * 2006-05-01 2007-11-15 Alexion Pharmaceuticals, Inc. Methods for the treatment of muscular dystrophy associated with dysferlin-deficiency
ES2523640T3 (en) 2006-06-21 2014-11-28 Musc Foundation For Research Development Addressing of complement factor H for the treatment of diseases
US7939636B2 (en) * 2006-08-11 2011-05-10 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in c-Src signaling pathways
US20090258442A1 (en) * 2006-08-31 2009-10-15 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
NZ575018A (en) 2006-09-05 2012-04-27 Alexion Pharma Inc Compositions for the treatment of antibody mediated neuropathies
EP2698166B1 (en) 2006-10-10 2015-09-30 Regenesance B.V. Complement inhibition for improved nerve regeneration
WO2008048689A2 (en) * 2006-10-20 2008-04-24 Alexion Pharmaceuticals, Inc. Methods for the treatment of muscular dystrophy associated with dysferlin-deficiency
TWI472535B (en) 2006-11-02 2015-02-11 Genentech Inc Humanized anti-factor d antibodies and uses thereof
EP1972639A3 (en) 2007-03-07 2008-12-03 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
EA200901211A1 (en) * 2007-03-22 2010-04-30 Новартис Аг ANTIGENS OF C5 PROTEIN AND THEIR APPLICATION
EP1975184A3 (en) 2007-03-26 2008-11-26 Cell Signaling Technology, Inc. Serine or threonine phosphorylation sites
US20080238709A1 (en) * 2007-03-28 2008-10-02 Faramarz Vaziri One-way communication apparatus with dynamic key generation
US7977462B2 (en) 2007-04-19 2011-07-12 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
EP1983003A3 (en) 2007-04-19 2009-03-11 Peter Hornbeck Tyrosine phosphorylation sites and antibodies specific for them
EP1983002A3 (en) 2007-04-19 2009-03-11 Peter Hornbeck Tyrosine phosphorylation sites and antibodies specific for them
US20090053831A1 (en) 2007-05-01 2009-02-26 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
CA2696164C (en) * 2007-08-13 2018-06-12 Vasgene Therapeutics, Inc. Cancer treatment using humanized antibodies that bind to ephb4
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
EP3741851A1 (en) 2007-10-18 2020-11-25 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
EP2062920A3 (en) 2007-11-21 2009-06-17 Peter Hornbeck Protein phosphorylation by basophilic serine/threonine kinases in insulin signalling pathways
US20090220991A1 (en) * 2008-02-29 2009-09-03 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
WO2009126306A2 (en) 2008-04-10 2009-10-15 Cell Signaling Technology, Inc. Compositions and methods for detecting egfr mutations in cancer
TWI564021B (en) 2008-04-11 2017-01-01 Chugai Pharmaceutical Co Ltd Repeated binding of antigen to antigen binding molecules
CR20170001A (en) 2008-04-28 2017-08-10 Genentech Inc ANTI FACTOR D HUMANIZED ANTIBODIES
US20090326070A1 (en) * 2008-05-01 2009-12-31 Complexa Inc. Vinyl substituted fatty acids
US8148088B2 (en) * 2008-07-18 2012-04-03 Abgent Regulation of autophagy pathway phosphorylation and uses thereof
CA2732782C (en) * 2008-08-05 2019-02-26 Novartis Ag Compositions and methods for antibodies targeting complement protein c5
AU2014201433B2 (en) * 2008-08-05 2016-05-26 Novartis Ag Compositions and methods for antibodies targeting complement protein C5
SI2379066T1 (en) * 2008-09-16 2014-08-29 Imuneks Farma Ilac Sanayi Ve Ticaret A.S. Use of opioid antagonists for the preparation of a medicament in the treatment of retinal degenerative diseases
TWI440469B (en) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
CA3035432A1 (en) 2008-11-10 2010-05-14 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
SI2881402T1 (en) 2009-02-12 2017-12-29 Cell Signaling Technology, Inc. Mutant ROS expression in human liver cancer
HUE062339T2 (en) 2009-02-13 2023-10-28 Immunomedics Inc Immunoconjugates with an intracellularly-cleavable linkage
RU2559526C2 (en) 2009-02-24 2015-08-10 Алексион Фармасьютикалз, Инк. Antibodies, containing therapeutic tpo/epo mimetic peptides
US20100248265A1 (en) * 2009-02-27 2010-09-30 The Salk Institute For Biological Studies Compositions and methods for diagnosis and treatment of cancer
RU2012102021A (en) 2009-06-23 2013-07-27 Алексион Фармасьютикалз, Инк. SPECIFIC ANTIBODIES THAT CONTACT PROTEIN PROTEINS
ME01699B (en) 2009-07-02 2014-09-20 Musc Found For Res Dev Methods of stimulating liver regeneration
IN2012DN01663A (en) 2009-09-16 2015-06-05 Immunomedics Inc
WO2011040894A1 (en) * 2009-10-01 2011-04-07 Mustafa Nevzat Ilaç Sanayii A.Ş. Topical compositions of opioid antagonists and methods for treating skin conditions therewith
AU2010314931A1 (en) 2009-11-05 2012-06-21 Taligen Therapeutics, Inc. Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
EP2506881B1 (en) 2009-12-02 2024-03-06 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
MX2012010116A (en) * 2010-03-01 2013-02-26 Alexion Pharma Inc Methods and compositions for treating degos' disease.
TWI667346B (en) * 2010-03-30 2019-08-01 中外製藥股份有限公司 Antibodies with modified affinity to fcrn that promote antigen clearance
TR201002473A2 (en) 2010-03-31 2011-09-21 Mustafa Nevzat �La� Sanay�� A.�. A method of treating herpes zoster disease using an opiate receptor antagonist.
WO2011137395A1 (en) 2010-04-30 2011-11-03 Rother Russell P Anti-c5a antibodies and methods for using the antibodies
US20140206849A1 (en) * 2010-04-30 2014-07-24 Alexion Pharmaceuticals, Inc. Antibodies having reduced immunogenicity in a human
BR112012029067A2 (en) 2010-05-14 2019-09-24 Univ Colorado Regents improved complement 2 receptor (cr2) target groups.
SG186397A1 (en) 2010-06-22 2013-01-30 Univ Colorado Regents Antibodies to the c3d fragment of complement component 3
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2012019132A2 (en) 2010-08-06 2012-02-09 Cell Signaling Technology, Inc. Anaplastic lymphoma kinase in kidney cancer
TW201241008A (en) * 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
PT3590949T (en) 2010-10-01 2022-08-02 Modernatx Inc Ribonucleic acids containing n1-methyl-pseudouracils and uses thereof
TWI761912B (en) 2010-11-30 2022-04-21 日商中外製藥股份有限公司 Antibody having calcium-dependent antigen-binding ability
EP2468295A1 (en) 2010-12-21 2012-06-27 Affiris AG Vaccines based on peptides of the complement protein C5a
MX352889B (en) 2011-02-25 2017-12-13 Chugai Pharmaceutical Co Ltd Fcî“riib-specific fc antibody.
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
US9867886B2 (en) 2011-04-15 2018-01-16 Snu R&Db Foundation Complex in which anti-cotinine antibody is bound to conjugate of cotinine and binding substance, and use thereof
CA2831572C (en) 2011-05-02 2019-11-26 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
US10039802B2 (en) 2011-06-22 2018-08-07 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2013047748A1 (en) 2011-09-30 2013-04-04 中外製薬株式会社 Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
TW201817745A (en) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance
SG11201401196WA (en) 2011-10-03 2014-05-29 Moderna Therapeutics Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
CN104080909A (en) 2011-11-30 2014-10-01 中外制药株式会社 Drug containing carrier into cell for forming immune complex
AU2012352180A1 (en) 2011-12-16 2014-07-31 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
EP3330288A1 (en) 2011-12-21 2018-06-06 Novartis AG Compositions and methods for antibodies targeting factor p
HUE041996T2 (en) 2012-02-20 2019-07-29 Swedish Orphan Biovitrum Ab Publ Polypeptides binding to human complement c5
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EP3505176A1 (en) 2012-04-02 2019-07-03 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
NZ629675A (en) 2012-04-06 2017-02-24 Omeros Corp Compositions and methods of inhibiting masp-1, masp-2 and/or masp-3 for treatment of paroxysmal nocturnal hemoglobinuria
US20150056193A1 (en) 2012-04-18 2015-02-26 Cell Signaling Technology, Inc. Egfr and ros1 kinase in cancer
NZ629473A (en) 2012-06-18 2017-02-24 Univ Leicester Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders
WO2014028560A2 (en) 2012-08-14 2014-02-20 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
AU2013302441B2 (en) 2012-08-17 2018-05-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
CN113831406A (en) 2012-08-24 2021-12-24 中外制药株式会社 Fc gamma RIIb specific Fc region variants
TW201418707A (en) * 2012-09-21 2014-05-16 Alexion Pharma Inc Screening assays for complement component C5 antagonists
JP6144355B2 (en) 2012-11-26 2017-06-07 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． Chemically modified mRNA
WO2014092804A1 (en) 2012-12-13 2014-06-19 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
JP6608702B2 (en) * 2013-01-31 2019-11-20 ソウル大学校産学協力団 C5 antibodies and methods for prevention and treatment of complement related diseases
RS56663B1 (en) 2013-03-14 2018-03-30 Alnylam Pharmaceuticals Inc Complement component c5 irna compositions and methods of use thereof
BR112015023212A2 (en) 2013-03-14 2017-11-21 Gill Parkash cancer treatment using antibodies that bind to cell surface grp78
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2014160958A1 (en) 2013-03-29 2014-10-02 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
CA2908350C (en) 2013-04-02 2023-08-08 Futa Mimoto Fc region variant
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
CN105683759B (en) 2013-08-07 2019-03-29 瑞颂医药公司 Atypia hemolytic uremic syndrome (aHUS) biomarker protein
WO2015023596A1 (en) 2013-08-12 2015-02-19 Genentech, Inc. Compositions and method for treating complement-associated conditions
JP2016531910A (en) * 2013-08-16 2016-10-13 アレクシオン ファーマシューティカルズ， インコーポレイテッド Treatment of transplant rejection by administration of complement inhibitors to pre-transplant organs
BR122023020080A2 (en) 2013-08-28 2023-12-26 Swedish Orphan Biovitrum Ab (Publ) BINDING OF STABLE POLYPEPTIDES TO C5 OF HUMAN COMPLEMENT
CN116987154A (en) 2013-08-28 2023-11-03 阿菲博迪公司 Binding polypeptides with mutated scaffolds
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2015054569A1 (en) 2013-10-10 2015-04-16 Viropharma Holdings Limited Methods of inhibiting the alternative pathway of complement immune system activation and compositions used therein
CA3107872A1 (en) 2013-12-12 2015-06-18 Alnylam Pharmaceuticals, Inc. Complement component irna compositions and methods of use thereof
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
EP3102701A1 (en) 2014-02-07 2016-12-14 Novartis AG Impact of genetic factors on disease progression and response to anti-c5 antibody in geographic atrophy
US9701743B2 (en) * 2014-02-20 2017-07-11 Allergan, Inc. Complement component C5 antibodies
CA2937236C (en) 2014-02-21 2023-03-07 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to trop-2 expressing cells
WO2015130416A1 (en) 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
EA032690B1 (en) 2014-02-25 2019-07-31 Ачиллион Фармасьютикалс, Инк. Aryl, heteroaryl and heterocyclic compounds for treatment of complement mediated disorders
KR20230149865A (en) * 2014-02-26 2023-10-27 알러간, 인코포레이티드 Complement component c5 antibodies
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
JP2017515811A (en) 2014-05-01 2017-06-15 ジェネンテック， インコーポレイテッド Anti-factor D antibody variants and methods of use thereof
MA51519A (en) 2014-05-05 2020-11-11 Regeneron Pharma HUMANIZED C5 AND C3 ANIMALS
PL3154561T3 (en) 2014-06-12 2019-12-31 Ra Pharmaceuticals, Inc. Modulation of complement activity
US9580495B2 (en) 2014-06-24 2017-02-28 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
US10568568B2 (en) 2014-08-27 2020-02-25 Capnia, Inc. Methods for immune globulin administration
EP3191591A1 (en) 2014-09-12 2017-07-19 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting complement component c5 and methods of use thereof
WO2016057398A1 (en) 2014-10-07 2016-04-14 Immunomedics, Inc. Neoadjuvant use of antibody-drug conjugates
EP3207058A1 (en) 2014-10-15 2017-08-23 Alexion Pharmaceuticals, Inc. Methods of culturing a cell
JP6479974B2 (en) 2014-10-15 2019-03-06 アレクシオン ファーマシューティカルズ， インコーポレイテッド A method to reproduce large-scale eculizumab-producing cell cultures
JP6948942B2 (en) * 2014-10-15 2021-10-13 アレクシオン ファーマシューティカルズ， インコーポレイテッド Methods and Uses for Shifting the Isoelectric Profile of Protein Products
WO2016094834A2 (en) 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. A method for treating a complement mediated disorder caused by an infectious agent in a patient
TW201809008A (en) 2014-12-19 2018-03-16 日商中外製藥股份有限公司 Anti-C5 antibodies and methods of use
US20180016327A1 (en) 2015-01-22 2018-01-18 Chugai Seiyaku Kabushiki Kaisha A Combination of Two or More Anti-C5 Antibodies and Methods of Use
JP6640229B2 (en) 2015-01-28 2020-02-05 ラ ファーマシューティカルズ インコーポレイテッドＲａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Modulators of complement activity
WO2016151558A1 (en) 2015-03-25 2016-09-29 Alexion Pharmaceuticals, Inc. A method for measuring the protease activity of factor d of the alternative complement pathway
TR201904903T4 (en) 2015-03-25 2019-05-21 Alexion Pharma Inc A method for measuring the protease activity of C3 and C5 convertase of the alternative complement pathway.
EP3286224A4 (en) 2015-04-22 2018-11-14 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
EP3288586A1 (en) 2015-05-01 2018-03-07 Alexion Pharmaceuticals, Inc. Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of kindney thansplant
WO2016196070A1 (en) 2015-06-03 2016-12-08 Children's Hospital Medical Center Compositions and methods for treating neonatal biliary atresia
EP3307318A4 (en) 2015-06-09 2019-01-16 Children's Hospital Medical Center Dosing algorithm for complement inhibitor
EP3307316A1 (en) 2015-06-12 2018-04-18 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
CA2983597A1 (en) 2015-06-25 2016-12-29 Immunomedics, Inc. Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
EP3313437A1 (en) * 2015-06-26 2018-05-02 Alexion Pharmaceuticals, Inc. A method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant
EP3316885B1 (en) 2015-07-01 2021-06-23 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
AR106018A1 (en) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
US10385097B2 (en) 2015-08-26 2019-08-20 Achillion Pharmaceuticals, Inc. Ether compounds for treatment of medical disorders
WO2017035357A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Phosphonate compounds for treatment of medical disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
AR105809A1 (en) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
EP3340983B1 (en) 2015-08-26 2023-10-04 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
WO2017035408A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
AR105808A1 (en) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc AMIDA COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
WO2017035361A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Disubstituted compounds for the treatment of medical disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
WO2017035351A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of medical disorders
US20170073399A1 (en) 2015-09-11 2017-03-16 Alexion Pharmaceuticals, Inc. Recombinant glycosylated eculizumab and eculizumab variants
CA2997745A1 (en) 2015-09-14 2017-03-23 Children's Hospital Medical Center Methods and compositions for treatment of gaucher disease via modulation of c5a receptor
US11203634B2 (en) 2015-10-07 2021-12-21 Alexion Pharmaceuticals, Inc. Methods of treating age-related macular degeneration in a patient comprising administering an anti-C5a antibody
TW201718014A (en) 2015-10-12 2017-06-01 諾華公司 Use of C5 inhibitors in Transplant Associated Microangiopathy
US20180311345A1 (en) 2015-10-30 2018-11-01 Alexion Pharmaceuticals, Inc. A method of inhibiting exacerbations of t cell-mediated allograft vasculopathy
JP2018536650A (en) 2015-10-30 2018-12-13 ジェネンテック， インコーポレイテッド Anti-factor D antibody variant conjugates and uses thereof
JP2018534930A (en) 2015-10-30 2018-11-29 ジェネンテック， インコーポレイテッド Anti-factor D antibodies and conjugates
ES2941640T3 (en) 2015-12-16 2023-05-24 Ra Pharmaceuticals Inc Modulators of complement activity
SG11201610782YA (en) 2015-12-18 2017-07-28 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use
EP3463461A4 (en) 2016-05-27 2020-05-20 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis
EP3463460A1 (en) 2016-06-07 2019-04-10 Novartis AG An anti-c5 antibody dosing regimen
EP3469083A1 (en) 2016-06-10 2019-04-17 Alnylam Pharmaceuticals, Inc. COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
IL309975A (en) 2016-06-14 2024-03-01 Regeneron Pharma Anti-c5 antibodies and uses thereof
TWI789369B (en) 2016-06-17 2023-01-11 日商中外製藥股份有限公司 Anti-c5 antibodies and methods of use
KR20190036520A (en) 2016-06-27 2019-04-04 아칠리온 파르마세우티칼스 인코포레이티드 Quinazoline and indole compounds for the treatment of medical disorders
JOP20170154B1 (en) 2016-08-01 2023-03-28 Omeros Corp Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
WO2018025982A1 (en) 2016-08-05 2018-02-08 中外製薬株式会社 Composition for prophylaxis or treatment of il-8 related diseases
JP7256741B2 (en) 2016-10-12 2023-04-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド Efficacy of anti-C5 antibodies in preventing antibody-mediated rejection in renal transplantation of sensitized recipients.
EP3526248A4 (en) 2016-10-17 2020-07-08 Musc Foundation for Research Development Compositions and methods for treating central nervous system injury
JP7173965B2 (en) 2016-10-19 2022-11-16 アレクシオン ファーマシューティカルズ， インコーポレイテッド Methods for quantifying unbound C5a in samples
EP3529618B1 (en) 2016-10-19 2020-12-02 Alexion Pharmaceuticals, Inc. A method of quantitating unbound c5 in a sample
US20200057046A1 (en) 2016-10-27 2020-02-20 Alexion Pharmaceuticals, Inc. Assay for c5b-9 deposition in complement-associated disorders
AU2017370692A1 (en) 2016-12-07 2019-06-06 Ra Pharmaceuticals, Inc. Modulators of complement activity
SG11201801401UA (en) 2017-01-31 2018-09-27 Chugai Pharmaceutical Co Ltd A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
EP3589287B1 (en) 2017-03-01 2022-09-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for treatment of medical disorders
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
IL294069B2 (en) 2017-03-01 2023-11-01 Achillion Pharmaceuticals Inc Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
WO2018175833A1 (en) 2017-03-23 2018-09-27 The Trustees Of The University Of Pennsylvania Anti-c5a antibodies and uses thereof
JP7247099B2 (en) 2017-03-31 2023-03-28 アレクシオン ファーマシューティカルズ， インコーポレイテッド Method for Simultaneous Quantitation of ALXN1210 and Eculizumab in Human Serum or Urine
US10376595B2 (en) 2017-04-03 2019-08-13 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5a activity
JP2020515643A (en) 2017-04-03 2020-05-28 インフラルクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＩｎｆｌａＲｘ ＧｍｂＨ Treatment of inflammatory diseases with inhibitors of C5a activity
JP2020517605A (en) 2017-04-19 2020-06-18 アレクシオン ファーマシューティカルズ， インコーポレイテッド Efficacy of anti-C5 antibody in preventing antibody-mediated rejection in sensitized kidney transplant recipients
WO2018193122A1 (en) * 2017-04-21 2018-10-25 Volution Immuno Pharmaceuticals Sa Coversin for the treatment of autoimmune blistering diseases
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
EP3630819B1 (en) 2017-05-22 2023-10-11 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of protein-losing enteropathy in patients
AU2018306612C1 (en) 2017-07-27 2023-11-09 Alexion Pharmaceuticals, Inc. High concentration anti-C5 antibody formulations
EP3692064A1 (en) 2017-10-04 2020-08-12 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of patients with membranoproliferative glomerulonephritis
CN111868081A (en) 2017-10-26 2020-10-30 亚力兄制药公司 Dosage and administration of anti-C5 antibodies for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (AHUS)
WO2019089922A1 (en) 2017-11-01 2019-05-09 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof
KR102551444B1 (en) 2017-11-29 2023-07-06 에프. 호프만-라 로슈 아게 Anti-drug antibody assay with suppressed target interference
CA3083113A1 (en) 2017-12-13 2019-06-20 Regeneron Pharmaceuticals, Inc. Anti-c5 antibody combinations and uses thereof
KR20200033348A (en) 2018-08-01 2020-03-27 추가이 세이야쿠 가부시키가이샤 A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
EP3841086A4 (en) 2018-08-20 2022-07-27 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
BR112021004263A2 (en) 2018-09-06 2021-05-25 Achillion Pharmaceuticals, Inc. morphic forms of danicopane
WO2020051532A2 (en) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
JP2022500427A (en) 2018-09-17 2022-01-04 国立大学法人京都大学 Administration of anti-C5 agents for the treatment of liver injury or liver failure
WO2020061496A1 (en) 2018-09-21 2020-03-26 Alexion Pharmaceuticals, Inc. Eculuzimab for the treatment of neuromyelitis opticae
KR20210093855A (en) 2018-09-25 2021-07-28 아칠리온 파르마세우티칼스 인코포레이티드 Conformational forms of complement factor D inhibitors
MX2021004994A (en) 2018-10-30 2021-06-15 Alexion Pharma Inc Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh).
US20210388070A1 (en) 2018-10-30 2021-12-16 Alexion Pharmaceuticals, Inc. Co-administration of a hyaluronidase and anti-c5 antibody for treatment of complement-associated conditions
US20220002393A1 (en) 2018-11-20 2022-01-06 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis in pediatric patients
CA3119234A1 (en) 2018-11-23 2020-05-28 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of c3 in a cell
EP3730617A1 (en) 2019-04-26 2020-10-28 Silence Therapeutics GmbH Nucleic acids for inhibiting expression of c3 in a cell
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
CN117838856A (en) 2019-01-25 2024-04-09 亚力兄制药公司 Dosage and administration of anti-C5 antibodies for the treatment of atypical hemolytic uremic syndrome (AHUS)
WO2020242849A1 (en) 2019-05-24 2020-12-03 Alexion Pharmaceuticals, Inc. Methods of treating vitiligo using an anti-c5 antibody
CN114466660A (en) 2019-07-31 2022-05-10 豪夫迈·罗氏有限公司 Dosage and administration regimen for treating or preventing C5-related diseases by using anti-C5 antibody covalenzumab
KR20240033090A (en) 2019-07-31 2024-03-12 에프. 호프만-라 로슈 아게 Dosage and administration regimen for the treatment or prevention of c5-related diseases by the use of the anti-c5 antibody crovalimab
WO2021026160A1 (en) 2019-08-05 2021-02-11 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis with eculizumab
EP4022060A1 (en) 2019-08-27 2022-07-06 Silence Therapeutics GmbH Nucleic acids for inhibiting expression of c3 in a cell
EP4048793A1 (en) 2019-10-22 2022-08-31 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof
WO2021133660A1 (en) 2019-12-23 2021-07-01 Alexion Pharmaceuticals, Inc. Methods of treating pregnancy-associated atypical hemolytic uremic syndrome using an anti-c5 antibody
WO2021154941A1 (en) 2020-01-31 2021-08-05 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
EP4114947A1 (en) 2020-03-05 2023-01-11 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
BR112022019090A2 (en) 2020-03-27 2022-11-08 Inflarx Gmbh C5A INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTION
CN116406287A (en) 2020-04-16 2023-07-07 巴黎公共医疗救助机构 Methods of treating complement-mediated disorders caused by viruses
JP2023523790A (en) 2020-04-30 2023-06-07 アルナイラム ファーマシューティカルズ， インコーポレイテッド COMPLEMENT FACTOR B (CFB) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
KR20230009431A (en) 2020-05-12 2023-01-17 알렉시온 파마슈티칼스, 인코포레이티드 Use of a complement factor D inhibitor alone or in combination with an anti-C5 antibody for the treatment of paroxysmal nocturnal hemoglobinuria
CN115803062A (en) 2020-06-03 2023-03-14 博泰康医药公司 Antibodies to trophoblast cell surface antigen 2 (TROP-2)
MX2022015899A (en) 2020-06-16 2023-01-24 Hoffmann La Roche Method for determining the free antigen of an antibody in a sample.
CN116194478A (en) 2020-06-24 2023-05-30 阿雷克森制药公司 Treatment of complement-associated disorders by Subcutaneous (SC) administration of anti-C5 antibodies
EP4178624A2 (en) 2020-07-07 2023-05-17 Bionecure Therapeutics, Inc. Maytansinoids as adc payloads and their use for the treatment of cancer
EP4181958A4 (en) * 2020-07-15 2024-03-06 Biosion Inc Antibodies binding c5 and uses thereof
WO2022150260A1 (en) 2021-01-05 2022-07-14 Alnylam Pharmaceuticals, Inc. COMPLEMENT COMPONENT 9 (C9) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
KR20230134533A (en) 2021-01-22 2023-09-21 알렉시온 파마슈티칼스, 인코포레이티드 Method for treating complement-mediated thrombotic microangiopathy using anti-C5 antibody
JP2024504390A (en) 2021-01-22 2024-01-31 バイワンキュア セラピューティクス， インコーポレイテッド Anti-HER-2/TROP-2 constructs and uses thereof
EP4342497A1 (en) 2021-05-10 2024-03-27 Kawasaki Institute of Industrial Promotion Antibody having reduced binding affinity for antigen
CA3220629A1 (en) 2021-05-28 2022-12-01 Tobin J. CAMMETT Methods for detecting cm-tma biomarkers
WO2023023220A1 (en) 2021-08-20 2023-02-23 Alexion Pharmaceuticals, Inc. Methods for treating sickle cell disease or beta thalassemia using a complement alternative pathway inhibitor
IL311146A (en) 2021-09-02 2024-04-01 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of complement factor b (cfb) in a cell
WO2023044370A2 (en) 2021-09-17 2023-03-23 Alnylam Pharmaceuticals, Inc. Irna compositions and methods for silencing complement component 3 (c3)
WO2023044048A1 (en) 2021-09-17 2023-03-23 Novartis Ag Methods for prevention of graft rejection in xenotransplantation
CA3234636A1 (en) 2021-10-29 2023-05-04 Alnylam Pharmaceuticals, Inc. Complement factor b (cfb) irna compositions and methods of use thereof
CN116712390B (en) * 2023-08-04 2023-11-14 上海览屹医药科技有限公司 High-concentration high-stability antibody preparation and preparation method thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4845198A (en) 1984-05-21 1989-07-04 Immunex Corporation Hybridoma antibody which binds IL-2 receptor
US4578335A (en) 1984-05-21 1986-03-25 Immunex Corporation Interleukin 2 receptor
US4686100A (en) * 1985-04-02 1987-08-11 The Board Of Trustees Of The Leland Stanford Junior University Method for the treatment of adult respiratory distress syndrome
US4816565A (en) 1985-08-13 1989-03-28 Tasuku Honjo Interleukin 2 receptor and a method for production thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5506247A (en) * 1988-04-15 1996-04-09 T Cell Sciences, Inc. Compounds that inhibit complement and/or suppress immune activity
US5173499A (en) * 1988-04-15 1992-12-22 T Cell Sciences, Inc. Compounds which inhibit complement and/or suppress immune activity
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2011450C (en) 1989-03-07 2002-06-04 Tadatsugu Taniguchi Recombinant b-chain of the il-2 receptor
US5135916A (en) * 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
DE3924924A1 (en) 1989-07-27 1991-02-07 Goetze Otto METHOD FOR DETECTING AND / OR QUANTITATIVELY DETERMINING COMPLEMENT PEPTIDE C5A AND / OR C5ADESARG
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
DE10399023I2 (en) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-binding proteins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
FR2671350A1 (en) 1991-01-08 1992-07-10 Adir NOVEL BENZISOXAZOLE AND BENZISOTHIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME.
GB9120467D0 (en) * 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
AU3095892A (en) * 1991-12-20 1993-07-28 Protein Design Labs, Inc. Human type antibody reactive with GPIIb/IIIa
EP0649468B1 (en) * 1992-06-24 2000-03-15 AdProTech plc Soluble cr1 derivatives

Also Published As

Publication number Publication date
ES2336051T3 (en) 2010-04-07
US6074642A (en) 2000-06-13
US6355245B1 (en) 2002-03-12
JP2005185286A (en) 2005-07-14
AU2474795A (en) 1995-11-29
JPH10500289A (en) 1998-01-13
KR100442019B1 (en) 2004-07-30
EP2112165A2 (en) 2009-10-28
EP2270046A2 (en) 2011-01-05
EP2298808A1 (en) 2011-03-23
EP0758904B1 (en) 2009-11-18
CA2189015C (en) 2010-04-13
JP3734266B2 (en) 2006-01-11
NL300433I1 (en) 2010-03-01
BR9507594A (en) 1997-09-16
JP5047996B2 (en) 2012-10-10
FR10C0016I1 (en) 2010-04-30
WO1995029697A1 (en) 1995-11-09
KR20040000388A (en) 2004-01-03
EP2270047A2 (en) 2011-01-05
DE69536017D1 (en) 2009-12-31
ATE448791T1 (en) 2009-12-15
EP0758904A4 (en) 2005-04-20
CA2189015A1 (en) 1995-11-09
CA2690298A1 (en) 1995-11-09
EP2112165A3 (en) 2011-03-23
JP2012095650A (en) 2012-05-24
EP0758904A1 (en) 1997-02-26
JP2006020633A (en) 2006-01-26
DE122009000075I1 (en) 2010-05-12
NL300433I2 (en) 2010-04-01
EP2270047A3 (en) 2011-03-23
JP4294596B2 (en) 2009-07-15
BR9507594B8 (en) 2015-06-02
JP2009165471A (en) 2009-07-30
EP2270046A3 (en) 2011-03-23
DK0758904T3 (en) 2010-01-18
KR100381128B1 (en) 2003-09-29
BR9507594B1 (en) 2010-08-10
PT758904E (en) 2010-02-10

Similar Documents

Publication Publication Date Title
FR10C0016I2 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF GLOMERULONEPHRITIS
DE3856594D1 (en) MEANS FOR THE TREATMENT OF ALZHEIMER DISEASE
ATE510562T1 (en) ANTI-AILIM ANTIBODIES FOR THE TREATMENT OF CROHN'S
MXPA02001911A (en) Human ctla 4 antibodies and their uses.
OA09478A (en) "Use of N-myristoyl- (S) -phenylalaine for the production of medicaments intended for the treatment of diseases involving myristoylation".
FR2670669B1 (en) INSTRUMENT FOR SURGICAL CORRECTION OF ASTIGMATISM.
DE69405919T2 (en) Compositions for the treatment of keratin fibers
DE69110713D1 (en) 7-Oxabicycloheptan-imidazole prostaglandin analogs, useful in the treatment of thrombotic and vasospastic diseases.
HK1017684A1 (en) Novel substituted 4-(1h-benzimidazol-2-yl)(1,4)diazepanes useful for the treatment of allergic diseases
IT1271567B (en) PROCEDURE FOR THE FURTHER TREATMENT OF SALCICCE
ATE113591T1 (en) 4-BENZYL-5-PHENYL-2,4-DIHYDRO-3H-1,2,4-TRIAZOLE-ONE AND THEIR USE AS ANTICONVULSANTS.
NO913117D0 (en) PROCEDURE FOR THE TREATMENT OF NECESSARY DISEASES.
ATE330604T1 (en) TREATMENT OF MANIC DISEASES
FR2715876B1 (en) Method for cleaning and / or disinfection and / or maintenance of medical or dental instruments and device for applying the method.
DE59006159D1 (en) USE OF MACROLACTONES AS ANTIALLERGICA.
DE689838T1 (en) Use of Diademosim 5 ', 5' '' - p1, p4-tetraphosphate for the treatment of ischemic myocardial diseases
FR2676622B1 (en) HAIR PROSTHESIS AND METHOD FOR THE TREATMENT OF CALVITIES USING THIS PROSTHESIS.
ATE249837T1 (en) CASPASE 8 INHIBITORS FOR IMMUNOSUPRESSION
FR2707165B1 (en) Application of taxoids to the treatment of parasitic diseases.
DE3869232D1 (en) BORNAN-3-SPIRO-L'-CYCLOPENTAN COMBATINGS AND THESE FRAGRANT COMPOSITIONS.
ITMI942076A0 (en) PROCEDURE FOR THE REDUCTION OF NICOTINE CONTENT THROUGH THE ACTION OF MICROORGANISMS
DE68914886D1 (en) Agent for the treatment of Raynaud's disease.
DE69133542D1 (en) Catheter for the treatment of prostate diseases
ITBO940254A0 (en) METHOD FOR THE IMPROVEMENT OF SOME FUNCTIONS OF THE HUMAN BODY.
ATE315583T1 (en) ANALOGUE OF THYMOSINE ALPHA 1